Pub Date : 2024-04-20DOI: 10.1016/j.jdin.2024.03.009
Kaya L. Curtis BA , Samantha Jo Albucker BA , Victoria De Barros BS , Yuqing Qiu MS , Shari R. Lipner MD, PhD
{"title":"Tumor development in patients with neurofibromatosis type 1: A retrospective cohort study including 644 patients","authors":"Kaya L. Curtis BA , Samantha Jo Albucker BA , Victoria De Barros BS , Yuqing Qiu MS , Shari R. Lipner MD, PhD","doi":"10.1016/j.jdin.2024.03.009","DOIUrl":"10.1016/j.jdin.2024.03.009","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"16 ","pages":"Pages 103-104"},"PeriodicalIF":0.0,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666328724000476/pdfft?md5=f8ad3812c3b68d6fd927cf89e383b458&pid=1-s2.0-S2666328724000476-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140756572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-16DOI: 10.1016/j.jdin.2024.03.026
Mischa J. Mallbris , Lea Krog Nymand BS , Yuki Maria Fukuda Andersen MD, PhD , Alexander Egeberg MD, PhD
Background
Alopecia areata (AA) and atopic dermatitis (AD) are chronic skin diseases where the suboptimal medication adherence (MA) may result in poor clinical outcomes.
Objective
To assess the impact of AA on MA among adults compared to AD.
Methods
Patient reported MA of adults with AA were compared with AD. Patients were identified from the Danish Skin Cohort, a nationwide prospective cohort of dermatological patients in Denmark. We used the Medication Adherence Report Scale- 5, a self-reporting questionnaire, to assess MA. Demographic and disease characteristics were collected. Logistic regression was conducted.
Results
Patients with AA reported higher MA than AD (mean 21.81 vs 18.29). Logistic regression analyses showed AA diagnosis had a statistically significant positive effect on MA (odds ratio = 3.94, 95% CI 2.01-8.89). Men reported significantly higher MA (odds ratio = 1.49, 95% CI 1.14-1.94). Current disease severity did not impact MA.
Limitations
Data were self-reported by patients. Data regarding the specific treatment undergone by patients were not available.
Conclusion
Patients with AA have significantly higher MA compared to patients with AD. The stability of AA patients’ symptoms may lead to higher MA due to a desire for disease control. Conversely, the sporadicity of AD symptoms could negatively affect adherence, causing fluctuations in medication use.
背景斑秃（AA）和特应性皮炎（AD）都是慢性皮肤病，不理想的用药依从性（MA）可能会导致不良的临床结果。方法将成人斑秃患者报告的 MA 与成人特应性皮炎患者报告的 MA 进行比较。患者是从丹麦皮肤队列（Danish Skin Cohort）中确定的，该队列是丹麦全国范围内皮肤病患者的前瞻性队列。我们使用自我报告问卷 "用药依从性报告量表-5 "来评估用药依从性。我们还收集了人口统计学特征和疾病特征。结果AA患者的MA值高于AD患者（平均值为21.81 vs 18.29）。逻辑回归分析表明，AA 诊断对 MA 有统计学意义上的积极影响（几率比 = 3.94，95% CI 2.01-8.89）。男性报告的 MA 明显更高（几率比 = 1.49，95% CI 1.14-1.94）。目前的疾病严重程度对 MA 没有影响。结论与 AD 患者相比，AA 患者的 MA 明显更高。AA患者症状的稳定性可能会导致患者希望控制病情，从而提高MA值。相反，AD 症状的不稳定性可能会对患者的用药依从性产生负面影响，导致用药量波动。
{"title":"Adult patients with alopecia areata report a significantly better medication adherence compared to those with atopic dermatitis: Results from a large cross-sectional cohort study","authors":"Mischa J. Mallbris , Lea Krog Nymand BS , Yuki Maria Fukuda Andersen MD, PhD , Alexander Egeberg MD, PhD","doi":"10.1016/j.jdin.2024.03.026","DOIUrl":"10.1016/j.jdin.2024.03.026","url":null,"abstract":"<div><h3>Background</h3><p>Alopecia areata (AA) and atopic dermatitis (AD) are chronic skin diseases where the suboptimal medication adherence (MA) may result in poor clinical outcomes.</p></div><div><h3>Objective</h3><p>To assess the impact of AA on MA among adults compared to AD.</p></div><div><h3>Methods</h3><p>Patient reported MA of adults with AA were compared with AD. Patients were identified from the Danish Skin Cohort, a nationwide prospective cohort of dermatological patients in Denmark. We used the Medication Adherence Report Scale- 5, a self-reporting questionnaire, to assess MA. Demographic and disease characteristics were collected. Logistic regression was conducted.</p></div><div><h3>Results</h3><p>Patients with AA reported higher MA than AD (mean 21.81 vs 18.29). Logistic regression analyses showed AA diagnosis had a statistically significant positive effect on MA (odds ratio = 3.94, 95% CI 2.01-8.89). Men reported significantly higher MA (odds ratio = 1.49, 95% CI 1.14-1.94). Current disease severity did not impact MA.</p></div><div><h3>Limitations</h3><p>Data were self-reported by patients. Data regarding the specific treatment undergone by patients were not available.</p></div><div><h3>Conclusion</h3><p>Patients with AA have significantly higher MA compared to patients with AD. The stability of AA patients’ symptoms may lead to higher MA due to a desire for disease control. Conversely, the sporadicity of AD symptoms could negatively affect adherence, causing fluctuations in medication use.</p></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"16 ","pages":"Pages 79-86"},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666328724000701/pdfft?md5=9554aad39cc2660e5765aedbf936afbe&pid=1-s2.0-S2666328724000701-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140795995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-10DOI: 10.1016/j.jdin.2024.03.025
Gil Yosipovitch MD , Brian S. Kim MD , Shawn G. Kwatra MD , Nicholas K. Mollanazar MD , Sonja Ständer MD , Takahiro Satoh MD, PhD , Pedro Mendes-Bastos MD , Tsen-Fang Tsai MD , Elizabeth Laws PhD , Michael C. Nivens PhD , Jennifer Maloney MD , Genming Shi PhD , Ashish Bansal MD, MBA , Ariane Dubost-Brama MD
Background
Phase 3 PRIME/PRIME2 trials independently demonstrated efficacy and an acceptable safety profile of dupilumab adults with moderate-to-severe prurigo nodularis.
Objective
To obtain a more precise estimate of onset and magnitude of treatment effect using PRIME/PRIME2 pooled data.
Methods
In PRIME/PRIME2, patients were randomized to dupilumab or placebo for 24 weeks. Pooled analysis assessed proportion of patients achieving clinically meaningful improvement in itch, clear/almost-clear skin, or both; at weeks 12 and 24; overall and by demographic subgroups and changes from baseline to week 24 in symptoms, signs, and quality of life.
Results
Patients receiving dupilumab (n = 153) vs placebo (n = 158) experienced significant improvements in all tested endpoints. At week 24, 90 (58.8%) dupilumab-treated vs 30 (19.0%) placebo-treated patients achieved clinically meaningful improvement in itch, 71 (46.4%) vs 27 (17.1%) clear/almost clear skin, and 54 (35.3%) vs 14 (8.9%) achieved both (P < .0001 for all). Treatment benefits were independent of baseline demographics. Safety to week 36 was generally consistent with the known dupilumab safety profile.
Limitations
On-treatment data limited to 24 weeks.
Conclusions
Pooled analysis confirmed improvements reported in individual trials and revealed earlier effect onset in itch and skin pain. Dupilumab treatment showed benefits across demographics.
{"title":"Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)","authors":"Gil Yosipovitch MD , Brian S. Kim MD , Shawn G. Kwatra MD , Nicholas K. Mollanazar MD , Sonja Ständer MD , Takahiro Satoh MD, PhD , Pedro Mendes-Bastos MD , Tsen-Fang Tsai MD , Elizabeth Laws PhD , Michael C. Nivens PhD , Jennifer Maloney MD , Genming Shi PhD , Ashish Bansal MD, MBA , Ariane Dubost-Brama MD","doi":"10.1016/j.jdin.2024.03.025","DOIUrl":"10.1016/j.jdin.2024.03.025","url":null,"abstract":"<div><h3>Background</h3><p>Phase 3 PRIME/PRIME2 trials independently demonstrated efficacy and an acceptable safety profile of dupilumab adults with moderate-to-severe prurigo nodularis.</p></div><div><h3>Objective</h3><p>To obtain a more precise estimate of onset and magnitude of treatment effect using PRIME/PRIME2 pooled data.</p></div><div><h3>Methods</h3><p>In PRIME/PRIME2, patients were randomized to dupilumab or placebo for 24 weeks. Pooled analysis assessed proportion of patients achieving clinically meaningful improvement in itch, clear/almost-clear skin, or both; at weeks 12 and 24; overall and by demographic subgroups and changes from baseline to week 24 in symptoms, signs, and quality of life.</p></div><div><h3>Results</h3><p>Patients receiving dupilumab (<em>n</em> = 153) vs placebo (<em>n</em> = 158) experienced significant improvements in all tested endpoints. At week 24, 90 (58.8%) dupilumab-treated vs 30 (19.0%) placebo-treated patients achieved clinically meaningful improvement in itch, 71 (46.4%) vs 27 (17.1%) clear/almost clear skin, and 54 (35.3%) vs 14 (8.9%) achieved both (<em>P</em> < .0001 for all). Treatment benefits were independent of baseline demographics. Safety to week 36 was generally consistent with the known dupilumab safety profile.</p></div><div><h3>Limitations</h3><p>On-treatment data limited to 24 weeks.</p></div><div><h3>Conclusions</h3><p>Pooled analysis confirmed improvements reported in individual trials and revealed earlier effect onset in itch and skin pain. Dupilumab treatment showed benefits across demographics.</p></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"16 ","pages":"Pages 163-174"},"PeriodicalIF":0.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666328724000683/pdfft?md5=471cd718507af14a71bd154edb3158dd&pid=1-s2.0-S2666328724000683-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140756718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-09DOI: 10.1016/j.jdin.2024.04.002
Paul Wasuwanich BSc , Robert S. Egerman MD , Tony S. Wen MD , Kiran Motaparthi MD
Background
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rarely described in the pregnant population, and knowledge of their impact on the mother/fetus is limited.
Objective
To describe SJS/TEN in pregnant women and to investigate the risk factors for developing SJS/TEN in pregnancy.
Methods
We utilized hospitalization data from the 2009–2020 National Inpatient Sample. Pregnancy hospitalizations and SJS/TEN involvement were identified by ICD-9/10 codes and analyzed by chi-square and logistic regression.
Results
We identified 650 pregnancies complicated by SJS/TEN requiring hospitalization. The median age was 28 years, and most were non-Hispanic White (55.2%). There were ≤10 cases associated with mortality. Most SJS/TEN cases (73.9%) occurred during the third trimester. HIV infection (OR = 9.49; P = .030), herpes simplex virus infection (OR = 2.49; P = .021), genitourinary tract infections (OR = 3.80; P < .001), malignant neoplasm (OR = 8.67; P = .031), and lupus erythematosus (OR = 41.94; P < .001) were associated with increased odds of developing SJS/TEN in pregnancy. Rates of preterm births were higher in the SJS/TEN cohort, 16.9% versus 8.2% (P < .001). Rates of pre-eclampsia, stillbirths, and post-term births were similar between the SJS/TEN versus non-SJS/TEN pregnancy cohorts.
Limitations
Limited cohort size.
Conclusions
SJS/TEN in pregnancy appears to be mild and is associated with favorable maternal-fetal outcomes, except for increased preterm birth.
{"title":"A nationwide study of Stevens–Johnson syndrome and toxic epidermal necrolysis in hospitalized pregnant women in the United States, 2009–2020","authors":"Paul Wasuwanich BSc , Robert S. Egerman MD , Tony S. Wen MD , Kiran Motaparthi MD","doi":"10.1016/j.jdin.2024.04.002","DOIUrl":"10.1016/j.jdin.2024.04.002","url":null,"abstract":"<div><h3>Background</h3><p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rarely described in the pregnant population, and knowledge of their impact on the mother/fetus is limited.</p></div><div><h3>Objective</h3><p>To describe SJS/TEN in pregnant women and to investigate the risk factors for developing SJS/TEN in pregnancy.</p></div><div><h3>Methods</h3><p>We utilized hospitalization data from the 2009–2020 National Inpatient Sample. Pregnancy hospitalizations and SJS/TEN involvement were identified by ICD-9/10 codes and analyzed by chi-square and logistic regression.</p></div><div><h3>Results</h3><p>We identified 650 pregnancies complicated by SJS/TEN requiring hospitalization. The median age was 28 years, and most were non-Hispanic White (55.2%). There were ≤10 cases associated with mortality. Most SJS/TEN cases (73.9%) occurred during the third trimester. HIV infection (OR = 9.49; <em>P</em> = .030), herpes simplex virus infection (OR = 2.49; <em>P</em> = .021), genitourinary tract infections (OR = 3.80; <em>P</em> < .001), malignant neoplasm (OR = 8.67; <em>P</em> = .031), and lupus erythematosus (OR = 41.94; <em>P</em> < .001) were associated with increased odds of developing SJS/TEN in pregnancy. Rates of preterm births were higher in the SJS/TEN cohort, 16.9% versus 8.2% (<em>P</em> < .001). Rates of pre-eclampsia, stillbirths, and post-term births were similar between the SJS/TEN versus non-SJS/TEN pregnancy cohorts.</p></div><div><h3>Limitations</h3><p>Limited cohort size.</p></div><div><h3>Conclusions</h3><p>SJS/TEN in pregnancy appears to be mild and is associated with favorable maternal-fetal outcomes, except for increased preterm birth.</p></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"16 ","pages":"Pages 175-182"},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666328724000671/pdfft?md5=3f9c31edebbd886b7627c43eca25d8b6&pid=1-s2.0-S2666328724000671-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140796748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-08DOI: 10.1016/j.jdin.2024.03.024
Ambika Nohria BA , Jill T. Shah BA , Deesha Desai BS , Lina Alhanshali BA , Jenne Ingrassia BA , Alisa Femia MD , Michael Garshick MD , Jerry Shapiro MD , Kristen I. Lo Sicco MD
{"title":"Alopecia areata and cardiovascular comorbidities: A cross-sectional analysis of the All of Us research program","authors":"Ambika Nohria BA , Jill T. Shah BA , Deesha Desai BS , Lina Alhanshali BA , Jenne Ingrassia BA , Alisa Femia MD , Michael Garshick MD , Jerry Shapiro MD , Kristen I. Lo Sicco MD","doi":"10.1016/j.jdin.2024.03.024","DOIUrl":"10.1016/j.jdin.2024.03.024","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"16 ","pages":"Pages 46-48"},"PeriodicalIF":0.0,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266632872400066X/pdfft?md5=46b20c6974b9ffc6bb0e2f3af364204a&pid=1-s2.0-S266632872400066X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140771439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-07DOI: 10.1016/j.jdin.2024.02.019
Tamara Gracia Cazaña MD, PhD , Josep Riera Monroig MD , Rosa Izu MD, PhD , Ignacio Yanguas MD, PhD , Marta Lorda Espés MD, PhD , María Pilar Sánchez Salas MD , Miguel Fernando García Gil MD , Alba Navarro Bielsa MD , Beatriz Aldea Manrique MD , Manuel Almenara Blasco MD , Francisco Javier García-Latasa de Araníbar MD, PhD , Victoria Fuentelsaz MD, PhD , Ana Morales Callaghan MD, PhD , Mariano Ara-Martín MD, PhD
Background
The treatment of psoriasis in patients with a personal history of cancer is a matter of debate and limited evidence is available to guide clinicians.
Objectives
To report a multicenter real-life experience of a group of patients with psoriasis undergoing treatment with guselkumab and a history of cancer.
Methods
We conducted a multicenter retrospective Spanish study enrolling patients with moderate-to-severe plaque psoriasis and neoplasia being treated with guselkumab for their psoriasis.
Results
Twenty patients with moderate-to-severe psoriasis and at least 12 weeks of ongoing treatment were included. For the analysis, a 52 week follow-up period was evaluated in terms of efficacy and safety. Most of the malignancies in these patients were solid tumors. The percentage of patients achieving psoriasis area and severity index ≤3 at week 12 and week 52 was 80% and 87.5%, respectively, whereas 68.8% of patients achieved psoriasis area and severity index ≤1. A 52-week survival rate of 100% in the study population was observed (n = 20), including those patients with concomitant active cancers (n = 14). No adverse effects or dropouts related to guselkumab safety profile were detected.
Limitations
Modest sample size and the retrospective nature of the study.
Conclusion
Guselkumab not only demonstrates high effectiveness in treating psoriasis but also exhibits a favorable safety profile in patients with neoplasms.
{"title":"Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab","authors":"Tamara Gracia Cazaña MD, PhD , Josep Riera Monroig MD , Rosa Izu MD, PhD , Ignacio Yanguas MD, PhD , Marta Lorda Espés MD, PhD , María Pilar Sánchez Salas MD , Miguel Fernando García Gil MD , Alba Navarro Bielsa MD , Beatriz Aldea Manrique MD , Manuel Almenara Blasco MD , Francisco Javier García-Latasa de Araníbar MD, PhD , Victoria Fuentelsaz MD, PhD , Ana Morales Callaghan MD, PhD , Mariano Ara-Martín MD, PhD","doi":"10.1016/j.jdin.2024.02.019","DOIUrl":"10.1016/j.jdin.2024.02.019","url":null,"abstract":"<div><h3>Background</h3><p>The treatment of psoriasis in patients with a personal history of cancer is a matter of debate and limited evidence is available to guide clinicians.</p></div><div><h3>Objectives</h3><p>To report a multicenter real-life experience of a group of patients with psoriasis undergoing treatment with guselkumab and a history of cancer.</p></div><div><h3>Methods</h3><p>We conducted a multicenter retrospective Spanish study enrolling patients with moderate-to-severe plaque psoriasis and neoplasia being treated with guselkumab for their psoriasis.</p></div><div><h3>Results</h3><p>Twenty patients with moderate-to-severe psoriasis and at least 12 weeks of ongoing treatment were included. For the analysis, a 52 week follow-up period was evaluated in terms of efficacy and safety. Most of the malignancies in these patients were solid tumors. The percentage of patients achieving psoriasis area and severity index ≤3 at week 12 and week 52 was 80% and 87.5%, respectively, whereas 68.8% of patients achieved psoriasis area and severity index ≤1. A 52-week survival rate of 100% in the study population was observed (<em>n</em> = 20), including those patients with concomitant active cancers (<em>n</em> = 14). No adverse effects or dropouts related to guselkumab safety profile were detected.</p></div><div><h3>Limitations</h3><p>Modest sample size and the retrospective nature of the study.</p></div><div><h3>Conclusion</h3><p>Guselkumab not only demonstrates high effectiveness in treating psoriasis but also exhibits a favorable safety profile in patients with neoplasms.</p></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"16 ","pages":"Pages 66-71"},"PeriodicalIF":0.0,"publicationDate":"2024-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666328724000580/pdfft?md5=3cbb5bbe8029dfc2b8d1e7a491ebd476&pid=1-s2.0-S2666328724000580-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140755875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-07DOI: 10.1016/j.jdin.2024.03.022
Jaya Manjunath BS , Viviane Liao BS , Anusha Kambala BS , Aaron Bao BA , Alexander L. Kollhoff MD , Emily Z. Ma BS , Brenda Umenita Imo MS , Hannah Cornman BS , Sriya V. Reddy BS , Kevin K. Lee BS , Weiying Lu BS , Selina M. Yossef BA , Madan M. Kwatra PhD , Shawn G. Kwatra MD
Background
Chronic pruritus (CP) is a poorly characterized condition associated with intense pruritus without a primary skin eruption. This condition tends to emerge more commonly in older adults, and there is limited research on triggering factors.
Objective
To explore the clinical characteristics and pathophysiology of CP following exposure to an immune stimulus.
Methods
Clinical characteristics and plasma samples were collected from 15 patients who developed CP following an immune stimulus such as checkpoint inhibitors or vaccination. A multiplex panel was used to analyze plasma cytokine concentrations within these patients.
Results
Most immunotherapy-treated patients experienced CP during treatment or after 21 to 60 days of receiving treatment, while vaccine-stimulated patients developed pruritus within a week of vaccination. Plasma cytokine analysis revealed elevated levels of 12 cytokines in patients with immune-stimulated CP compared to healthy controls. Notably, T helper 2 (Th2) related cytokines interleukin (IL)-5 (fold change 2.65; q < 0.25) and thymic stromal lymphopoietin (fold change 1.61 q < 0.25) were upregulated.
Limitations
Limitations of this study include limited sample size, particularly in the plasma cytokine assay.
Conclusions and Relevance
This study reveals triggers of CP development and describes alterations in blood Th2 markers in patients with CP, including IgE, increased blood eosinophils, and cytokines IL-5 and thymic stromal lymphopoietin.
{"title":"Immune stimulus exposure as a trigger for the development of chronic pruritus and circulating blood type 2 inflammation","authors":"Jaya Manjunath BS , Viviane Liao BS , Anusha Kambala BS , Aaron Bao BA , Alexander L. Kollhoff MD , Emily Z. Ma BS , Brenda Umenita Imo MS , Hannah Cornman BS , Sriya V. Reddy BS , Kevin K. Lee BS , Weiying Lu BS , Selina M. Yossef BA , Madan M. Kwatra PhD , Shawn G. Kwatra MD","doi":"10.1016/j.jdin.2024.03.022","DOIUrl":"10.1016/j.jdin.2024.03.022","url":null,"abstract":"<div><h3>Background</h3><p>Chronic pruritus (CP) is a poorly characterized condition associated with intense pruritus without a primary skin eruption. This condition tends to emerge more commonly in older adults, and there is limited research on triggering factors.</p></div><div><h3>Objective</h3><p>To explore the clinical characteristics and pathophysiology of CP following exposure to an immune stimulus.</p></div><div><h3>Methods</h3><p>Clinical characteristics and plasma samples were collected from 15 patients who developed CP following an immune stimulus such as checkpoint inhibitors or vaccination. A multiplex panel was used to analyze plasma cytokine concentrations within these patients.</p></div><div><h3>Results</h3><p>Most immunotherapy-treated patients experienced CP during treatment or after 21 to 60 days of receiving treatment, while vaccine-stimulated patients developed pruritus within a week of vaccination. Plasma cytokine analysis revealed elevated levels of 12 cytokines in patients with immune-stimulated CP compared to healthy controls. Notably, T helper 2 (Th2) related cytokines interleukin (IL)-5 (fold change 2.65; q < 0.25) and thymic stromal lymphopoietin (fold change 1.61 q < 0.25) were upregulated.</p></div><div><h3>Limitations</h3><p>Limitations of this study include limited sample size, particularly in the plasma cytokine assay.</p></div><div><h3>Conclusions and Relevance</h3><p>This study reveals triggers of CP development and describes alterations in blood Th2 markers in patients with CP, including IgE, increased blood eosinophils, and cytokines IL-5 and thymic stromal lymphopoietin.</p></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"16 ","pages":"Pages 97-102"},"PeriodicalIF":0.0,"publicationDate":"2024-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666328724000646/pdfft?md5=699ff9b1b7fe91272ac4c23f22d918c6&pid=1-s2.0-S2666328724000646-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140777255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-07DOI: 10.1016/j.jdin.2023.12.014
Arbie Sofia P. Merilleno MD , Francisco D. Rivera IV MD, FPDS , Maria Sharlene P. Temblique MD, FPDS
{"title":"Association between the disease severity and quality of life of patients with psoriasis in a tertiary government hospital in the Philippines: A retrospective cross-sectional study","authors":"Arbie Sofia P. Merilleno MD , Francisco D. Rivera IV MD, FPDS , Maria Sharlene P. Temblique MD, FPDS","doi":"10.1016/j.jdin.2023.12.014","DOIUrl":"10.1016/j.jdin.2023.12.014","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"16 ","pages":"Pages 42-45"},"PeriodicalIF":0.0,"publicationDate":"2024-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666328724000567/pdfft?md5=9f0c834ddb263d546d2d5021f6f7ad70&pid=1-s2.0-S2666328724000567-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140761270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-06DOI: 10.1016/j.jdin.2024.03.020
Caitlin A. Kearney BS , Sreejan Saha BA , Maria Teresa Mata Vivas BA , Joel M. Gelfand MD, MSCE , Jessica Garelik DO , Kristen I. Lo Sicco MD , Michael Garshick MD, MS
{"title":"Characterization of cardiometabolic risk awareness among patients with psoriasis: A quality improvement survey study","authors":"Caitlin A. Kearney BS , Sreejan Saha BA , Maria Teresa Mata Vivas BA , Joel M. Gelfand MD, MSCE , Jessica Garelik DO , Kristen I. Lo Sicco MD , Michael Garshick MD, MS","doi":"10.1016/j.jdin.2024.03.020","DOIUrl":"10.1016/j.jdin.2024.03.020","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"16 ","pages":"Pages 72-74"},"PeriodicalIF":0.0,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666328724000634/pdfft?md5=1e77ecc7120fa8bca5fb32856cbc5720&pid=1-s2.0-S2666328724000634-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140796654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号